Short answer
BCR-ABL1 testing looks for the fusion gene that creates the Philadelphia chromosome. It is the key test for chronic myeloid leukemia and can also show up in some acute leukemias. In practice, the test is ordered because a CBC, blood smear, exam, or prior diagnosis raises a focused leukemia question, and quantitative PCR is then used to follow treatment response over time.
How the test is used
The first job is diagnosis support: a very high white count, left shift, basophilia, or splenomegaly can make CML a concern. After diagnosis, the same marker becomes a monitoring tool. Many patients are followed with quantitative BCR-ABL1 PCR on a regular schedule so clinicians can track molecular response and adjust therapy if the trend is not moving as expected.
Methods you may see
| Method | Common role | Main point |
|---|---|---|
| Qualitative PCR | Checks whether BCR-ABL1 transcript is present. | Often used when the question is simply "is it there?" |
| Quantitative RT-PCR | Measures transcript level over time. | The main monitoring tool for treated CML. |
| FISH | Looks for the fusion in cells. | Useful when a chromosome-level view is needed. |
| Karyotype | Looks at the chromosomes directly. | Can show the Philadelphia chromosome and additional changes. |
What a result means
A positive result supports a diagnosis of BCR-ABL1-associated leukemia, but the exact meaning depends on the setting. A new positive test after a suspicious CBC points toward hematology evaluation. A low but detectable result during therapy means something different: the trend, the assay method, the lab's reporting scale, and prior values matter a lot more than a single number.
Questions before acting
- Was this ordered because of CBC or smear findings, symptoms, or known CML monitoring?
- Is the result qualitative or quantitative, and is it reported on the International Scale?
- What is the baseline transcript level, and what follow-up interval is recommended?
- If the result is positive, does the next step require hematology review, marrow testing, or therapy monitoring?
What the result still cannot prove
A BCR-ABL1 result can help classify a myeloproliferative process, but it does not by itself replace the rest of the blood count, smear, and clinical context that shape the final diagnosis.
FAQ
What is BCR-ABL1?
BCR-ABL1 is an abnormal fusion gene created when parts of chromosomes 9 and 22 join together. It is the molecular hallmark of the Philadelphia chromosome.
Is BCR-ABL1 the same as the Philadelphia chromosome?
They are closely linked. The Philadelphia chromosome is the chromosome change, and BCR-ABL1 is the fusion gene created by that change.
Does a positive BCR-ABL1 test mean I have CML?
A positive result strongly supports a BCR-ABL1-associated leukemia, but the full diagnosis still depends on the clinical setting, blood counts, smear, and sometimes marrow testing.
Why is quantitative PCR repeated so often?
Because small changes in transcript level help show whether treatment is working and whether the molecular response is on track.
Can BCR-ABL1 testing be used as a general cancer screen?
No. It is a targeted test used when there is a specific leukemia question, not a broad screen for healthy people.
What should I ask if my result is low-level positive?
Ask how the assay was performed, what the prior baseline was, whether the value is on the International Scale, and when the next test should happen.
Related guides: CBC blood test, peripheral blood smear, CALR and MPL testing, and JAK2 testing.